Safety and Immunogenicity After Primary and Booster Inactivated SARS-Cov-2 Vaccination in Patients with Autoimmune Liver Diseases
نویسندگان
چکیده
Background and AimsSARS-CoV-2 vaccines-associated autoimmune liver diseases have been reported in several case reports. However, the safety immunogenicity after primary booster inactivated SARS-CoV-2 vaccination patients with (AILD) is still unknown.
منابع مشابه
Whole-inactivated SARS-CoV-2 vaccines: from fear to hope
Undoubtedly, vaccination can be one of the promising approaches to control infectious diseases such as the COVID-19 pandemic. Inactivated viral vaccines have a history of "vaccine-induced enhanced disease", which may occur when neutralizing antibodies bind to viral antigens without blocking or clearing the infection. This can cause additional inflammation through the mechanisms described for ot...
متن کاملGastrointestinal Manifestations in Patients Infected with SARS-CoV-2
Coronavirus disease 2019, caused by severe acute respiratory syndrome coronavirus 2, has recently become the number one problem affecting global health. Coronavirus disease 2019 is principally recognized by its respiratory manifestations; however, recent studies have shown an increasing number of patients with gastrointestinal complaints like diarrhea, nausea, vomiting, and abdominal discomfort...
متن کاملthe past hospitalization and its association with suicide attempts and ideation in patients with mdd and comparison with bmd (depressed type) group
چکیده ندارد.
Coagulopathies after vaccination against SARS-CoV-2: The sole solution might lead to another problem
The common reported adverse impacts of COVID-19 vaccination include the injection site’s local reaction followed by various non-specific flu-like symptoms. Nevertheless, uncommon cases of vaccine-induced immune thrombotic thrombocytopenia (VITT) and cerebral venous sinus thrombosis (CVST) following viral vector vaccines (ChAdOx1 nCoV-19 vaccine, Ad26.COV2 vaccine) have been reported. This liter...
متن کاملSafety and immunogenicity of human papillomavirus vaccination in juvenile patients with rheumatic diseases
Methods A prospective controlled observational trial was initiated in female patients and healthy controls aged 12-18 years. Patients and controls were vaccinated (0, 1, and 6 months) and followed for 12 months. HPV16 and 18specific antibody concentrations were measured using a fluorescent microspheres-based multiplex immuno-assay after 12 months. Adverse events (AE’s) 2 weeks after each vaccin...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of clinical and translational hepatology
سال: 2023
ISSN: ['2310-8819', '2225-0719']
DOI: https://doi.org/10.14218/jcth.2023.00049